Guillermo Garcia-Manero

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 108:3271-9. 2006
  2. ncbi Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy
    Guillermo Garcia-Manero
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 25:427-35. 2012
  3. ncbi Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77025, USA
    J Clin Oncol 30:2204-10. 2012
  4. ncbi Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Am J Hematol 87:692-701. 2012
  5. ncbi RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression
    Ashakumary Lakshmikuttyamma
    Cancer Stem Cell Research Group, University of Saskatchewan, Saskatoon, SK, Canada
    J Hematol Oncol 2:28. 2009
  6. ncbi Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome
    Wanlong Ma
    Department of Hematology Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    BMC Med Genet 11:163. 2010
  7. ncbi Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Invest 23:635-42. 2005
  8. ncbi Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside
    Guillermo Garcia-Manero
    Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer 97:3010-6. 2003
  9. ncbi Future directions for the use of hypomethylating agents
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 42:S50-9. 2005
  10. ncbi Progress in myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:S286-92. 2009

Research Grants

  1. Cell Cycle Controlling Genes in Adult Acute Lymphoma
    Guillermo Garcia Manero; Fiscal Year: 2005
  2. Phase1/11 study of 5-aza-2'-deoxycytidine and valproic *
    Guillermo Garcia Manero; Fiscal Year: 2005
  3. Phase I study of 5-aza-2?-deoxycitidine in acute lymphocytic leukemia
    Guillermo Garcia Manero; Fiscal Year: 2007

Collaborators

Detail Information

Publications126 found, 100 shown here

  1. ncbi Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 108:3271-9. 2006
    ..In summary, this combination of epigenetic therapy in leukemia was safe and active, and was associated with transient reversal of aberrant epigenetic marks...
  2. ncbi Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy
    Guillermo Garcia-Manero
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 25:427-35. 2012
    ..These results form the bases of the next SWOG front-line trial in AML. Here, we present the rationale for such combination and the studies that led to the support of this concept including both in vitro models and initial phase 1 trials...
  3. ncbi Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77025, USA
    J Clin Oncol 30:2204-10. 2012
    ..To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)...
  4. ncbi Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Am J Hematol 87:692-701. 2012
    ..Options include cytarabine based therapy, transplantation and participation on a clinical trial...
  5. ncbi RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression
    Ashakumary Lakshmikuttyamma
    Cancer Stem Cell Research Group, University of Saskatchewan, Saskatoon, SK, Canada
    J Hematol Oncol 2:28. 2009
    ..In CML blast crisis cell lines RIZ1 represses insulin-like growth factor-1 expression and autocrine signaling. Together these observations suggest that RIZ1 may have a role in the chronic phase to blast crisis transition in CML...
  6. ncbi Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome
    Wanlong Ma
    Department of Hematology Oncology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA
    BMC Med Genet 11:163. 2010
    ..The G/G genotype of the single-nucleotide polymorphism (SNP) rs1617640 in the erythropoietin (EPO) promoter has been shown to be associated with decreased EPO expression. We examined the association of rs1617640 genotype with MDS...
  7. ncbi Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Invest 23:635-42. 2005
    ..In this article, we provide a brief introduction to the field of histone deacetylation inhibition in cancer and review the most relevant clinical data so far published...
  8. ncbi Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside
    Guillermo Garcia-Manero
    Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer 97:3010-6. 2003
    ..To evaluate the activity and toxicity of weekly Schering 54301, a polyethylene glycol formulation of interferon- alpha-2b (PEG-IFN-alpha-2b), with cytosine arabinoside (ara-C) in patients with chronic myelogenous leukemia (CML)...
  9. ncbi Future directions for the use of hypomethylating agents
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 42:S50-9. 2005
    ..This review discusses the potential use of methylation reversing agents in the treatment of solid tumors and in benign hematologic disorders along with the rationale for combination therapies using hypomethylating agents...
  10. ncbi Progress in myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:S286-92. 2009
    ....
  11. ncbi A prognostic score for patients with lower risk myelodysplastic syndrome
    G Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leukemia 22:538-43. 2008
    ..2 months (95% CI 13-18). In summary, this analysis indicates that it is possible to identify patients with lower risk MDS and poor prognosis who may benefit from early intervention...
  12. ncbi Epigenetics of acute lymphocytic leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 46:24-32. 2009
    ..In this review, we describe the role of epigenetic alterations in ALL from a translational perspective...
  13. ncbi Leukemia and lymphoma: what is the role for intrathecal prophylactic treatment in adults?
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Houston, TX 77030, USA
    Expert Rev Neurother 4:S25-31. 2004
    ..be applied to adult patients with leukemia? In addition and as an extension of the adult leukemia patient discussion, is there a role for intrathecal prophylaxis in patients with lymphoma, a population at risk for neoplastic meningitis?..
  14. ncbi Demethylating agents in myeloid malignancies
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Oncol 20:705-10. 2008
    ..It is proposed that hypomethylating agents work by inducing reexpression of epigenetically silenced genes. Here, we provide an up-to-date summary of the clinical experience with these drugs...
  15. ncbi Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:981-9. 2008
    ..In summary, MGCD0103 was safe and had antileukemia activity that was mechanism based in patients with advanced leukemia...
  16. ncbi DNA methylation patterns at relapse in adult acute lymphocytic leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Cancer Res 8:1897-903. 2002
    ..To study the role of DNA methylation in relapse mechanisms in acute lymphocytic leukemia (ALL), we have compared the methylation status of five genes at the time of initial presentation and at first relapse in 25 adult patients with ALL...
  17. ncbi Hypomethylating agents and other novel strategies in myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Box 428, 1515 Holcombe Blvd, PO Box 301402, Houston, TX 77025, USA
    J Clin Oncol 29:516-23. 2011
    ....
  18. ncbi DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia
    Guillermo Garcia-Manero
    Departments of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2217-24. 2002
    ..Aberrant methylation of promoter-associated CpG islands is an epigenetic oncogenic mechanism. The objective of this study was to define the methylation characteristics of patients with acute lymphocytic leukemia (ALL)...
  19. ncbi A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Box 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Haematologica 87:804-7. 2002
    ..We report the results of a phase I study of dose escalation of idarubicin with amifostine and high-dose ara-C in patients with relapsed or refractory AML or myelodysplastic syndrome (MDS)...
  20. ncbi Treatment of higher-risk myelodysplastic syndrome
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, USA
    Semin Oncol 38:673-81. 2011
    ..This review will summarize results from current available therapies and discuss potential needs and ongoing research in the area of treatment of higher-risk MDS...
  21. ncbi Integrating care for patients with lower risk myelodysplastic syndrome
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, USA
    Semin Oncol 38:658-66. 2011
    ....
  22. ncbi Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 86:490-8. 2011
    ..Options include cytarabine-based therapy, transplantation, and participation on a clinical trial...
  23. ncbi Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
    Guillermo Garcia-Manero
    University of Texas, MD Anderson Cancer Center, Box 428, 1515 Holcombe Blvd, Houston, TX 77025, USA
    J Clin Oncol 29:2521-7. 2011
    ....
  24. ncbi Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:695-702. 2003
    ..This epigenetic modification has been associated with gene silencing, malignant transformation, and aging. It is not known whether there are epigenetic differences between pediatric patients and adult patients with ALL...
  25. ncbi Prognosis of myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77025, USA
    Hematology Am Soc Hematol Educ Program 2010:330-7. 2010
    ..This review summarizes current prognostic models of MDS and new molecular alterations with potential prognostic potential...
  26. ncbi A pilot pharmacokinetic study of oral azacitidine
    G Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer, Houston, TX 77030, USA
    Leukemia 22:1680-4. 2008
    ..4% of historic s.c. exposure. No severe drug-related toxicities were observed. These data suggest that oral azacitidine is bioavailable in humans and should be studied in formal phase 1 trials...
  27. ncbi A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1234-41. 2003
    ....
  28. ncbi Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
    Apostolia Tsimberidou
    Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Leuk Res 27:893-7. 2003
    ..CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML...
  29. ncbi Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 109:52-7. 2007
    ..We conclude that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS...
  30. ncbi Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
    ..Molecular CRs were achieved in both groups (SCT or no SCT). Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed...
  31. ncbi Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 106:1569-80. 2006
    ..CONCLUSIONS: The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients...
  32. ncbi The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy
    Yue Wei
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 16:3923-32. 2010
    ..We hypothesized, therefore, that combination of an HDACi with a proapoptotic agent, such as the Bcl-2 homology domain-3 mimetic GX15-070, could result in enhanced antileukemia activity...
  33. ncbi Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
    Karen W L Yee
    Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:6615-24. 2005
    ..CONCLUSION: Further assessment of ABT-751, especially in combination with other agents, in patients with acute leukemias is warranted...
  34. ncbi Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
    Stefan Faderl
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77230 1402, USA
    J Clin Oncol 28:2755-60. 2010
    ..Efficacy and toxicity profile of orally administered clofarabine were evaluated in patients with higher-risk myelodysplastic syndrome (MDS)...
  35. ncbi Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
    Francis J Giles
    Department of Leukemia, Box 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 21:1722-7. 2003
    ..A prospective, randomized study was conducted in patients aged 50 years or older with untreated, adverse karyotype, acute myeloid leukemia (AML) to assess troxacitabine-based regimes as induction therapy...
  36. ncbi A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:2908-17. 2004
    ..As alkylating agents are important antileukemia drugs, a Phase I and pharmacokinetic study of VNP40101M was conducted in patients with refractory or relapsed leukemias or poor-risk myelodysplastic syndromes (MDS)...
  37. ncbi Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
    Alfonso Quintas Cardama
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:248-55. 2007
    ..Homoharringtonine (HHT) is a cephalotaxus alkaloid that inhibits the synthesis of proteins leading to apoptosis. Intravenous HHT has demonstrated activity in patients with chronic myeloid leukemia (CML) after failure with interferon...
  38. ncbi Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:265-73. 2007
    ..In this study, the authors update their experience with decitabine in patients with MDS and analyze the cytogenetic response patterns and prognostic factors associated with decitabine therapy...
  39. ncbi Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
    Stefan Faderl
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 108:45-51. 2006
    ..However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation...
  40. ncbi Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, U T MD Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 148:386-93. 2010
    ..These data further indicate that plasma may be a good target to evaluate for minimal residual disease using cCD52/cCD20 levels...
  41. ncbi Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate
    Jean Pierre J Issa
    Department of Leukemia and Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:3948-56. 2005
    ..To determine the activity of decitabine, a DNA methylation inhibitor, in imatinib-refractory or intolerant chronic myelogenous leukemia...
  42. ncbi Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:2099-108. 2005
    ..The objectives of this study were to update the long-term experience with imatinib in patients who had accelerated-phase CML and to compare outcomes with historic experience...
  43. ncbi Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 104:1979-88. 2004
    ..0001); the survival advantage was confirmed by multivariate analysis (hazard ratio, 0.19; P <.0001)...
  44. ncbi Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Blood 113:6330-7. 2009
    ..Incorporation of monoclonal antibodies directed against CD20 into frontline chemotherapy regimens warrants investigation...
  45. ncbi Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia
    Hui Yang
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:1892-8. 2009
    ..68, P= .003) and overall survival (hazard ratio=2.69, P= .002). In conclusion, detection of epigenetic alterations allows the identification of patients with ALL with standard risk but with poor prognosis...
  46. ncbi Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 12:244-51. 2012
    ..The overall 4-week mortality rate was 9%. In conclusion, BIDFA is active and safe in heavily pretreated patients with myeloid malignancies...
  47. ncbi Current and future management options for myelodysplastic syndromes
    Jeffrey Bryan
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Drugs 70:1381-94. 2010
    ..This review focuses on supportive care modalities, the approved agents indicated for the treatment of MDS and future directions for the treatment of MDS, including agents under clinical investigation...
  48. ncbi A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome
    Elias Jabbour
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1236-44. 2011
    ..The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome...
  49. ncbi A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase
    Alfonso Quintas Cardama
    Department of Leukemia, The University of Texas M D Anderson Cancer Center Houston, TX 77030, USA
    Leuk Lymphoma 48:283-9. 2007
    ..Median survival was 5 months (range, 2 - 20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP...
  50. ncbi A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
    Stefan Faderl
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:1638-45. 2008
    ..4 months vs 5.8 months; P = .1). Clofarabine plus low-dose cytarabine has a higher response rate than clofarabine alone with comparable toxicity. This trial is registered at www.clinicaltrials.gov as no. NCT00088218...
  51. ncbi Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
    Andres O Soriano
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2302-8. 2007
    ..VPA blood levels were higher in responders (P < .005). In conclusion, the combination studied is safe and has significant clinical activity. This clinical trial was registered at www.clinicaltrials.gov as no. NCT00326170...
  52. ncbi Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:504-10. 2009
    ....
  53. ncbi Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    Apostolia M Tsimberidou
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA
    J Clin Oncol 26:196-203. 2008
    ..We conducted a phase I-II trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) in these diseases...
  54. ncbi Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1060-6. 2008
    ..Increased histone acetylation was observed at all doses. Antioxidant gene expression may confer vorinostat resistance. Further evaluation of vorinostat in AML/MDS is warranted...
  55. ncbi Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies
    Jean Pierre J Issa
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 103:1635-40. 2004
    ..There was no correlation between P15 methylation at baseline or after therapy and response to decitabine. We conclude that decitabine is effective in myeloid malignancies, and low doses are as or more effective than higher doses...
  56. ncbi Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia
    Andreia A Canalli
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 29:881-5. 2005
    ..003). These results indicate that differences in DNA methylation of specific molecular pathways may contribute to the prognostic differences known to occur between pediatric and adult patients with ALL...
  57. ncbi Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
    Apostolia M Tsimberidou
    Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 52:449-52. 2003
    ..Grade 3/4 toxicities, including sepsis, neutropenic fever, and nausea/vomiting, were equivalent with MFAC and IA. CONCLUSIONS: Post-remission therapy with MFAC is feasible and well tolerated in patients with AML...
  58. ncbi Outcome of patients with acute myelogenous leukemia after second salvage therapy
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Cancer 104:547-54. 2005
    ..The authors analyzed the outcome of patients with AML undergoing second salvage therapy, and identified prognostic factors associated with response and survival...
  59. ncbi Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:1287-92. 2004
    ....
  60. ncbi Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
    Stefan Faderl
    Department of Leukemia, Box 428, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 105:940-7. 2005
    ..The combination of clofarabine with ara-C is safe and active. Cellular pharmacology data support the biochemical modulation strategy...
  61. ncbi Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Blood 120:4840-5. 2012
    ..The studies reviewed are registered at www.clinicaltrials.gov as 2009-0172 (NCT00926731) and 2009-0217 (NCT00952588)...
  62. ncbi Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2636-42. 2003
    ..This was most likely because approximately 90% of patients receiving IFN-alpha plus ara-C changed to imatinib therapy after a median of 8 months into therapy...
  63. ncbi Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2134-41. 2002
    ....
  64. ncbi Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
    Francis Giles
    Department of Leukemia, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 98:888-93. 2003
    ..This finding suggests that imatinib combination regimens may improve the prognosis in CML...
  65. ncbi Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:68-75. 2004
    ..Multivariate analyses were conducted to assess the independent prognostic effect of therapy (imatinib versus other) on survival...
  66. ncbi Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results
    Hagop M Kantarjian
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:2177-87. 2002
    ..We identified pretreatment and treatment-associated factors that were associated with higher major cytogenetic response rates and with improved survival...
  67. ncbi Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome
    Karen W L Yee
    Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 30:813-22. 2006
    ..The recommended phase II regimen is Triapine 105 mg/m2/day followed by ara-C 600 mg/m2/day for 5 consecutive days every 3-6 weeks...
  68. ncbi Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
    Deborah A Thomas
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:3880-9. 2010
    ....
  69. ncbi Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Hagop Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer 112:837-45. 2008
    ..Response rates in chronic myeloid leukemia (CML) are now reported based on the cumulative incidence of a single-time best response. The study aim was to examine the significance of different response criteria for CML on imatinib therapy...
  70. ncbi Activity of alemtuzumab in patients with CD52-positive acute leukemia
    Raoul Tibes
    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:2645-51. 2006
    ..An evaluation in patients with a better prognosis, in combination with other agents or as part of consolidation therapy, is warranted...
  71. ncbi Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Elias Jabbour
    Department of Leukemia and, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 110:2991-5. 2007
    ..CAs occur in Ph-negative cells in a small percentage of patients with newly diagnosed CML treated with IM. In rare instances, these could reflect the emergence of a new malignant clone...
  72. ncbi Biphenotypic acute leukaemia: a case series
    Ahmed Aribi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston TX 77030, USA
    Br J Haematol 138:213-6. 2007
    ..Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%...
  73. ncbi Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Rich
    Apostolia M Tsimberidou
    Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1711-20. 2003
    ..CONCLUSIONS: The study regimen had activity and significant toxicity in patients with RS or fludarabine-refractory CLL. It was not clearly better compared with hyper-CVXD alone in this patient population...
  74. ncbi Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis
    Alfonso Quintas-Cardama
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:4760-6. 2009
    ..To investigate the safety and efficacy of the combination of lenalidomide and prednisone in patients with myelofibrosis (MF)...
  75. ncbi Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
    Elihu Estey
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe, Box 428, Houston, 77030, USA
    Blood 107:3469-73. 2006
    ..ATRA plus ATO may serve as an alternative to chemotherapy in low-risk untreated APL (eg, in older patients) and, when combined with GO, may improve outcome in high-risk patients...
  76. ncbi Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 11:7817-24. 2005
    ..A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease...
  77. ncbi Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia
    Yasuhiro Oki
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:899-906. 2007
    ..A Phase II study was performed on low-dose decitabine, a DNA methyltransferase inhibitor, in combination with imatinib in patients with CML in accelerated phase (AP) and myeloid blastic phase (BP)...
  78. ncbi Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status
    Carlos Bueso-Ramos
    Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1402, USA
    J Clin Oncol 23:3932-9. 2005
    ..001, .04, and .03 respectively). CONCLUSION: Expression of a triad of cell cycle regulatory proteins that includes p73, p15, and p57Kip2 has prognostic value in adult patients with ALL independently of the methylation status of each gene...
  79. ncbi Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
    Elias Jabbour
    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:480-2. 2006
    ..SBT is still a rare event, probably less common than that observed with IFN-alpha therapy. Continuous monitoring of patients treated with imatinib is mandatory...
  80. ncbi Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience
    Bryan Hennessy
    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 77:209-14. 2004
    ..SM is rare and has no effective standard of care. Collaboration among academic centers to accrue enough patients to evaluate novel therapeutic strategies is needed...
  81. ncbi Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers
    Fadi Braiteh
    Department of Investigational Cancer Therapeutics Phase I Program, Division of Cancer Medicine and Quantitative Sciences, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 14:6296-301. 2008
    ..On the basis of this evidence, we conducted a phase I study of the combination of 5-AZA and valproic acid in patients with advanced cancers...
  82. ncbi Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor
    Blanca Sanchez-Gonzalez
    Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Blood 108:1174-82. 2006
    ..Of importance, the cellular and molecular effects observed were independent of the sequence used. In summary, the combination of an anthracycline with an HDACI should have significant clinical activity in patients with leukemia...
  83. ncbi Epigenetic therapy of leukemia: An update
    Nitin Jain
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Biochem Cell Biol 41:72-80. 2009
    ..In this review, we will focus on recent advances in epigenetic therapy in leukemia...
  84. ncbi Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
    Carmen Fava
    Department of Leukemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:5058-63. 2009
    ..These results suggest that achievement of a MCyR without concomitant CHR is associated with poor outcome...
  85. ncbi Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:1899-905. 2009
    ..The authors hypothesized that low doses of the hypomethylating agent 5-azacitidine may maximize the graft-versus-leukemia effect and may be tolerated well after allogeneic transplantation (HSCT)...
  86. ncbi A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia
    Tapan M Kadia
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 150:72-82. 2010
    ..The combination of vorinostat and idarubicin is generally tolerable and active in patients with advanced leukaemia and should be studied in the front-line setting...
  87. ncbi A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Francis Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 12:4628-35. 2006
    ..LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle...
  88. ncbi Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 113:2154-60. 2009
    ..In conclusion, imatinib dose escalation can induce sustained responses in a subset of patients with cytogenetic failure and a previous cytogenetic response to standard-dose imatinib...
  89. ncbi Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:1050-6. 2003
    ..Troxacitabine has significant single-agent activity. This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan...
  90. ncbi Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer 97:1920-8. 2003
    ..SU5416 is a small-molecule RTK inhibitor (RTKI) that targets VEGFR-2, c-kit, and fms-related tyrosine kinase Flk2...
  91. ncbi Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome
    Francis Giles
    Department of Leukemia, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA
    Acta Haematol 108:164-7. 2002
  92. ncbi Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 109:3214-8. 2007
    ..Liposomal cytarabine given via intrathecal route concomitantly with systemic chemotherapy that crosses the blood-brain barrier such as high-dose MTX and cytarabine can result in significant neurotoxicity...
  93. ncbi Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia
    Ahmed Aribi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 109:1355-9. 2007
    ..Arsenic trioxide (ATO) is an effective agent for the salvage of patients with recurrent APL, and gemtuzumab ozogamicin (GO) has shown activity in patients with APL...
  94. ncbi HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target
    Xin Han
    Department of Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 20:54-62. 2007
    ..05) and p21 (P<0.001) were expressed significantly more often in Ph+ pre-B ALL. HDM4 and HDM2 showed no correlation with Ph status. HDM4 expression in most cases of adult pre-B ALL suggests that HDM4 is a potential therapeutic target...
  95. ncbi Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
    Constantine S Tam
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:516-8. 2008
    ..These results suggest that patients receiving 2TKI with no cytogenetic response at 3 to 6 months should be considered for alternative therapies...
  96. ncbi Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:1478-84. 2010
    ..In conclusion, a significant number of CD34+ cells can be safely collected in patients with CML who are on imatinib therapy, but CD34+ cell yields improve when imatinib is temporarily withheld...
  97. ncbi Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia
    Koyu Hoshino
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Leuk Res 33:1361-6. 2009
    ..53). Overall, our results indicate that JUNB expression is downregulated in advanced phase CML through a mechanism independent from DNA methylation...
  98. ncbi Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, 77230 1402, USA
    Br J Haematol 134:58-60. 2006
    ..The EPI is reproducible and useful...
  99. ncbi Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center
    Yasuhiro Oki
    Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:880-4. 2006
    ..51, P = .049). These results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease...
  100. ncbi Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate
    Yumin Hu
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 116:2732-41. 2010
    ..Such a combination strategy may be an effective therapeutic regimen and have potential clinical application in leukemia...
  101. ncbi Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia
    Francis J Giles
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Box 428, Houston, TX 77030, USA
    Leuk Res 27:1077-83. 2003
    ..Based on these clinical, pharmacokinetic, and pharmacodynamic data, Triapine warrants further study in patients with hematologic malignancies...

Research Grants4

  1. Cell Cycle Controlling Genes in Adult Acute Lymphoma
    Guillermo Garcia Manero; Fiscal Year: 2005
    ..abstract_text> ..
  2. Phase1/11 study of 5-aza-2'-deoxycytidine and valproic *
    Guillermo Garcia Manero; Fiscal Year: 2005
    ..Decitabine will be generously provided by SuperGen (r). Valproic acid is an FDA approved anti-convulsant. ..
  3. Phase I study of 5-aza-2?-deoxycitidine in acute lymphocytic leukemia
    Guillermo Garcia Manero; Fiscal Year: 2007
    ..In this proposal, we plan to develop a new form of low-dose chemotherapy, decitabine, for these patients. Early results indicate that this is active and safe. ..